Oscillatory Positive Expiratory Pressure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Facemask OPEP Devices, Mouthpiece OPEP Devices, Bottle OPEP Devices), By Application (Asthma, Atelectasis, Bronchitis, Other), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.89 Billion
CAGR (2026-2031)	6.76%
Fastest Growing Segment	Asthma
Largest Market	North America
Market Size (2031)	USD 4.28 Billion

Market Overview

The Global Oscillatory Positive Expiratory Pressure Market will grow from USD 2.89 Billion in 2025 to USD 4.28 Billion by 2031 at a 6.76% CAGR. Oscillatory Positive Expiratory Pressure (OPEP) devices are non-invasive medical aids designed to facilitate mucus clearance by generating resistance and vibrations during exhalation, thereby loosening bronchial secretions. The market is primarily propelled by the rising global prevalence of chronic respiratory conditions such as cystic fibrosis, bronchiectasis, and Chronic Obstructive Pulmonary Disease (COPD), alongside an aging population increasingly susceptible to lung function decline. These fundamental drivers are distinct from temporary market trends, as they represent a structural healthcare necessity for long-term disease management and the prevention of respiratory complications in home-care settings.

Despite this strong demand, a significant challenge hindering broader market expansion is the inconsistency in reimbursement coverage across different regions, which can restrict patient access to these essential therapies. This economic barrier is particularly concerning given the vast scale of the patient population requiring effective airway clearance. According to the World Health Organization, in 2025, chronic respiratory diseases affected 81.7 million people in the WHO European Region. This statistic highlights the critical magnitude of the respiratory burden that OPEP manufacturers must address while navigating complex regulatory and financial landscapes.

Key Market Drivers

The escalating global prevalence of Chronic Obstructive Pulmonary Disease (COPD) and asthma is the primary catalyst for the Global Oscillatory Positive Expiratory Pressure Market, creating a sustained necessity for effective airway clearance. This structural demand is driven by the chronic nature of these respiratory pathologies, which require consistent mucus mobilization to prevent severe exacerbations and hospital admissions. According to the Centers for Disease Control and Prevention, May 2025, in the 'Chronic Obstructive Pulmonary Disease in Adults Age 18 and Older: United States, 2023' report, the age-adjusted prevalence of diagnosed COPD in adults was 3.8%. This clinical burden is further amplified by environmental risks that accelerate lung function decline; according to the American Lung Association, April 2025, in the 'State of the Air 2025' report, 156.1 million people in the United States lived in areas with unhealthy levels of air pollution, directly expanding the population susceptible to respiratory complications requiring non-pharmacological interventions.

Technological innovations in portable and gravity-independent device designs are the second major driver, significantly enhancing patient adherence compared to traditional physiotherapy. Modern OPEP devices have evolved into compact, position-independent systems that allow patients to perform therapy without restricting mobility, a crucial factor for broad home-care adoption. This shift toward user-centric design is reshaping market competition, with manufacturers prioritizing efficacy and ease of use to capture market share. The industry's success in meeting these high standards is evident; according to Monaghan Medical Corporation, December 2025, in a press release regarding the '2025 AARC Zenith Award', the company secured its 10th win in 11 years, underscoring the critical value placed on reliable, innovative respiratory technologies. These advancements differentiate premium devices, driving market growth by ensuring consistent therapy delivery outside of clinical settings.

Download Free Sample Report

Key Market Challenges

The inconsistency in reimbursement coverage across different regions presents a substantial economic barrier that directly impedes the expansion of the Global Oscillatory Positive Expiratory Pressure Market. Although these devices are essential for effective airway clearance, variable healthcare policies often result in high out-of-pocket costs for patients, which sharply reduces device adoption rates. This financial strain is particularly impactful because the primary user base frequently consists of elderly individuals or those managing lifelong conditions on fixed incomes. Consequently, when patients cannot afford these necessary therapies due to coverage gaps, the market fails to convert the high clinical demand into sustainable revenue growth.

This disconnect between patient necessity and purchasing power limits the industry's ability to serve its total addressable market effectively. The scale of this unaddressed need is evident in recent prevalence data which underscores the vast potential user base. According to the American Lung Association, in 2025, over 35 million people in America were living with chronic lung disease. This statistic highlights the magnitude of the patient population that requires ongoing respiratory support yet may face restricted access to OPEP therapy, thereby capping the market's potential trajectory despite favorable disease prevalence trends.

Key Market Trends

The Adoption of Combined OPEP and Nebulizer Therapies is emerging as a critical trend to alleviate the substantial daily treatment burden faced by patients with chronic respiratory conditions. By enabling simultaneous mucus clearance and aerosol medication delivery, this integrated approach significantly reduces the time required for therapy regimens, which is a key factor in promoting consistent patient compliance. The technical viability of this dual-modality treatment is supported by recent performance data; according to Trudell Medical International, June 2024, in the 'Combination Therapy (OPEP and Nebulizer) to Provide Focus to Mucus Clearance' report, a laboratory study demonstrated that combined therapy delivered more than 80% of the medication in the respirable droplet size range while maintaining a treatment time similar to OPEP therapy alone. This efficiency ensures that patients receive effective pharmacological intervention without compromising the mechanical benefits of oscillatory pressure, driving the market toward multi-functional device ecosystems.

Simultaneously, the Integration of Smart Digital Connectivity for Adherence Tracking is reshaping the competitive landscape by evolving mechanical devices into connected respiratory health platforms. Manufacturers are increasingly prioritizing digital therapeutics that monitor usage patterns and provide real-time feedback to address the pervasive challenge of non-adherence in home-care settings. This data-driven shift is validated by improved clinical indicators associated with connected care; according to Health Tech World, February 2025, in the 'New national data shows improved respiratory outcomes with digital therapeutics' article, patients utilizing a respiratory digital care plan for four months or more experienced a 41% increase in their wellness scores. Such significant improvements highlight the growing market value of integrating connectivity into OPEP strategies to ensure measurable, long-term therapeutic success.

Segmental Insights

The Asthma segment currently represents the fastest-growing category in the Global Oscillatory Positive Expiratory Pressure Market, driven by the escalating global prevalence of respiratory disorders reported by the World Health Organization. This expansion is supported by the increasing adoption of airway clearance therapies to manage mucus accumulation in patients with severe asthma or overlap syndromes. Furthermore, the shift towards home-based care has amplified the demand for portable therapeutic devices. As medical professionals prioritize comprehensive respiratory management to prevent exacerbations, the integration of these non-invasive solutions into standard treatment protocols continues to accelerate segment growth.

Regional Insights

North America maintains a leading position in the Global Oscillatory Positive Expiratory Pressure Market due to the high prevalence of chronic respiratory ailments, including Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. The region benefits from robust healthcare infrastructure and comprehensive reimbursement structures that ensure widespread patient access to essential therapies. Furthermore, rigorous regulatory standards enforced by the U.S. Food and Drug Administration ensure high product safety, fostering trust among healthcare providers. The concentration of major device manufacturers within the United States and Canada also streamlines distribution and strengthens regional market stability.

Recent Developments

• In December 2024, PARI GmbH was distinguished as a "Brand of the Century" by the "German Standards" evaluation, reaffirming its position as a leading manufacturer in the respiratory therapy market. The recognition highlighted the company’s enduring product quality and innovative strength in the field of inhalation therapy and respiratory devices, which includes its range of oscillatory positive expiratory pressure systems. This award acknowledged the company's long-standing contribution to setting standards in medical technology and supporting patient health over decades.
• In October 2024, Monaghan Medical Corporation was honored with the 2024 Zenith Award by the American Association for Respiratory Care. This accolade recognized the company’s excellence in the respiratory care profession, specifically highlighting the quality of its product portfolio, which includes widely used oscillatory positive expiratory pressure devices. The award, voted on by respiratory therapists, underscored the company's commitment to providing innovative devices and support to healthcare professionals and patients managing acute and chronic pulmonary illnesses.
• In July 2024, Trudell Medical International announced the expansion of its global operations with the establishment of a new subsidiary, Trudell Medical Australia. This strategic move was designed to provide the company with a direct presence in the Australian market, facilitating the distribution of its respiratory health devices, including its leading oscillatory positive expiratory pressure products, to patients with chronic respiratory conditions. The expansion aimed to improve access to airway clearance therapies for the estimated millions of Australians living with asthma and chronic obstructive pulmonary disease.
• In April 2024, a new oscillatory positive expiratory pressure device named HydroBubble was launched following a collaboration between the Cystic Fibrosis Team at South Warwickshire University NHS Foundation Trust and Hydrate for Health. The device was designed to provide a more sustainable and cost-effective alternative to traditional bubble positive expiratory pressure treatments used for chest physiotherapy. The reusable device produces vibrations in the lungs to help loosen and move secretions, aiming to support patients with respiratory conditions such as cystic fibrosis. The launch marked a significant innovation in respiratory care within the region.

Key Market Players

• Monaghan Medical Corporation
• Hill‑Rom Holdings, Inc.
• ICU Medical, Inc.
• Respironics, Inc.
• Teleflex Incorporated
• GlaxoSmithKline plc
• Telecare Services, Inc.
• Summit Medical Products, Inc.
• Fisher & Paykel Healthcare Corporation Limited

By Type	By Application	By Region
Facemask OPEP Devices Mouthpiece OPEP Devices Bottle OPEP Devices	Asthma Atelectasis Bronchitis Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Oscillatory Positive Expiratory Pressure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Oscillatory Positive Expiratory Pressure Market, By Type:

• Facemask OPEP Devices
• Mouthpiece OPEP Devices
• Bottle OPEP Devices

• Oscillatory Positive Expiratory Pressure Market, By Application:

• Asthma
• Atelectasis
• Bronchitis
• Other

• Oscillatory Positive Expiratory Pressure Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE